Orbimed Advisors LLC Argenx Se Transaction History

Orbimed Advisors LLC

$2.93 Billion
Q3 2025

A detailed history of Orbimed Advisors LLC transactions in Argenx Se stock. As of the latest transaction made, Orbimed Advisors LLC holds 172,300 shares of ARGX stock, worth $156 Million. This represents 4.34% of its overall portfolio holdings.

Number of Shares

172,300

Previous 208,000 17.16%

Holding current value

$156 Million

Previous $115 Million 10.84%

% of portfolio

4.34%

Previous 4.09%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	SELL	$538.64 - $768.0 $19.2 Million - $27.4 Million	-35,700 Reduced 17.16%	172,300 $127 Million
Q2 2025 Aug 14, 2025	BUY	$532.27 - $656.65 $691,951 - $853,645	1,300 Added 0.63%	208,000 $115 Million
Q1 2025 May 15, 2025	BUY	$571.0 - $671.75 $9.71 Million - $11.4 Million	17,000 Added 8.96%	206,700 $122 Million
Q4 2024 Feb 14, 2025	SELL	$520.52 - $638.33 $7.7 Million - $9.45 Million	-14,800 Reduced 7.24%	189,700 $117 Million
Q3 2024 Nov 14, 2024	SELL	$434.22 - $551.9 $2 Million - $2.54 Million	-4,600 Reduced 2.2%	204,500 $111 Million

Q2 2024 Aug 14, 2024	BUY	$356.01 - $451.55 $20.5 Million - $26 Million	57,500 Added 37.93%	209,100 $89.9 Million
Q1 2024 May 15, 2024	BUY	$356.95 - $413.29 $23.9 Million - $27.7 Million	67,000 Added 79.2%	151,600 $59.7 Million
Q4 2023 Feb 14, 2024	BUY	$338.91 - $506.01 $17.6 Million - $26.3 Million	52,000 Added 159.51%	84,600 $32.2 Million
Q2 2023 Aug 14, 2023	SELL	$360.14 - $422.58 $4.29 Million - $5.03 Million	-11,900 Reduced 26.74%	32,600 $12.7 Million
Q1 2023 May 15, 2023	BUY	$334.23 - $403.65 $9.46 Million - $11.4 Million	28,300 Added 174.69%	44,500 $16.6 Million
Q4 2022 Feb 14, 2023	SELL	$342.17 - $402.31 $86.7 Million - $102 Million	-253,500 Reduced 93.99%	16,200 $6.14 Million
Q3 2022 Nov 14, 2022	BUY	$343.2 - $395.75 $26 Million - $30 Million	75,700 Added 39.02%	269,700 $95.2 Million
Q2 2022 Aug 15, 2022	BUY	$269.58 - $378.88 $6.52 Million - $9.17 Million	24,200 Added 14.25%	194,000 $73.5 Million
Q1 2022 May 16, 2022	BUY	$254.45 - $351.06 $43.2 Million - $59.6 Million	169,800 New	169,800 $53.5 Million
Q2 2020 Aug 14, 2020	SELL	$127.44 - $232.72 $3.64 Million - $6.65 Million	-28,591 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$108.83 - $165.23 $24.8 Million - $37.6 Million	-227,709 Reduced 88.84%	28,591 $3.77 Million
Q4 2019 Feb 14, 2020	SELL	$106.59 - $164.21 $5.77 Million - $8.88 Million	-54,100 Reduced 17.43%	256,300 $41.1 Million
Q2 2019 Aug 14, 2019	SELL	$115.0 - $141.58 $5.85 Million - $7.21 Million	-50,900 Reduced 14.09%	310,400 $43.9 Million
Q1 2019 May 15, 2019	SELL	$98.85 - $134.59 $28.3 Million - $38.5 Million	-286,300 Reduced 44.21%	361,300 $45.1 Million
Q4 2018 Feb 14, 2019	SELL	$63.81 - $109.82 $4.54 Million - $7.82 Million	-71,200 Reduced 9.91%	647,600 $62.2 Million
Q3 2018 Nov 14, 2018	BUY	$75.5 - $96.63 $9.02 Million - $11.5 Million	119,500 Added 19.94%	718,800 $54.5 Million
Q2 2018 Aug 14, 2018	BUY	$74.84 - $100.16 $7.43 Million - $9.95 Million	99,300 Added 19.86%	599,300 $49.7 Million
Q3 2017 Nov 14, 2017	BUY	$19.81 - $22.61 $9.91 Million - $11.3 Million	500,000	500,000 $11.3 Million

Others Institutions Holding ARGX

# of Institutions

525

Shares Held

26M

Call Options Held

589K

Put Options Held

320K

View Full List

About ARGENX SE

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $50.2B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

More about ARGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Orbimed Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Orbimed Advisors LLC with notifications on news.

Account

Orbimed Advisors LLC Argenx Se Transaction History